Empagliflozin in Heart Failure Dialysis Patients

Empagliflozin is not still approved for glomerular filtration rate < 20 cc/min/1.73m2. Considering the cardiac and renal benefits of this drug, the evaluation of the safety and efficacy of Empagliflozin for heart failure dialysis patients seems to be mandatory.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Heart Failure Cardiovascular Diseases Heart Diseases Hemodialysis

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Nooshin Dalili

Tehran, 1666663421, Iran

About this study

Heart failure dialysis patients with residual renal function will be followed up on Empagliflozin based on echocardiographic parameters, pro-brain natriuretic peptide levels, diuresis volume, and serum acidity.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Heart failure on dialysis with residual renal function

Exclusion criteria

Dialysis patients with no residual urine

Treatment and study plan

Empagliflozin10Mg Tab

Drug

10 mg daily

Other names: Abide

Primary outcomes

Brain Natriuretic Peptide

Time frame: one month after administration

serum level

Sponsors and collaborators

Lead sponsor

Shahid Beheshti University of Medical Sciences

Other

Registry information

Official study title

Safety and Efficacy of Empagliflozin on Heart Failure Dialysis Patients

Important dates

Study start: 2023
Primary completion: 2025
Study completion: 2025
First posted: Aug 1, 2023
Registry last updated: Jun 6, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed